Navigation Links
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
Date:12/12/2011

SUNDAY, Dec. 11 (HealthDay News) -- A study assessing intravenous infusion of the drug salbutamol in patients with acute respiratory distress syndrome was halted because the treatment did not improve patient outcomes and was associated with an increased risk of death, researchers say.

Acute respiratory distress syndrome (ARDS) occurs in about 14 percent of patients who require being placed on mechanical ventilation. The death rate among patients with ARDS is high -- 40 to 60 percent -- and survivors have a substantial decrease in their quality of life.

However, "routine use of [beta-2] agonist therapy in mechanically ventilated patients with ARDS cannot be recommended," the researchers wrote in an article published in the Dec. 12 online edition of The Lancet.

The British study included 326 patients who received either salbutamol (also known as albuterol) or a placebo within 72 hours of developing ARDS, and the treatment continued for up to seven days. But the study was stopped after 55 (34 percent) of the 161 patients in the salbutamol group died, compared with 38 (23 percent) of the 163 patients in the placebo group.

Overall, the death rate was 47 percent higher in the salbutamol group than in the placebo group, the report indicated.

In addition, patients in the salbutamol group had fewer ventilator-free days and organ failure-free days than those in the placebo group.

"Our findings show that intravenous salbutamol given to patients with early ARDS significantly increased 28-day mortality, and reduced ventilator-free days and duration of organ support compared with those given placebo," Fang Gao Smith and Gavin Perkins of the University of Warwick, and colleagues, explained in a journal news release.

The authors added that the therapy was "poorly tolerated" by patients because it was linked to heart rhythm abnormalities and lactic acidosis (a dangerous buildup of lactic acid in the blood). "These findings were unexpected," the researchers noted.

The findings of the cancelled study may be sufficient to change treatment of patients with ARDS, Dr. B. Taylor Thompson, of Massachusetts General Hospital and Harvard Medical School, wrote in an accompanying editorial.

"[Beta-2] agonist treatment in patients with ARDS should be limited to the treatment of clinically important reversible airway obstruction and should not be part of routine care," Thompson recommended.

More information

The U.S. National Heart, Lung, and Blood Institute has more about acute respiratory distress syndrome.

-- Robert Preidt

SOURCE: The Lancet, news release, Dec. 11, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Few With Acute Kidney Injury See Specialists, Study Finds
2. TAST 2011 -- Thrombolysis and Acute Stroke Treatment in 2011: Preparing for the next decade
3. Dendritic cells protect against acute pancreatitis
4. FDA funds Rochester researchers to give chronic and acute pain clinical trials a makeover
5. Unsaturated fat breakdown leads to complications of acute pancreatitis in obese patients
6. Miriam Hospital researchers pilot new acute hepatitis C screening strategy for HIV-infected patients
7. Death Rate Higher in Minorities With Acute Leukemia
8. Regional differences in the care of acute stroke patients
9. Alcohol consumption in relation to acute pancreatitis
10. Drinking just 1 measure of spirits increases the risk of acute pancreatitis
11. $12 million NIH grant to study acute lung injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology: